Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.

ABSTRACT:

Background

For many patients with resected epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), current standard of care (SoC) is adjuvant chemotherapy; however, disease recurrence remains high. Based on positive results from ADAURA (NCT02511106), adjuvant osimertinib was approved for treatment of resected stage IB‒IIIA EGFRm NSCLC.

Objective

The aim was to assess the cost-effectiveness of adjuvant osimertinib in patients with resected EGFRm NSCLC.

Methods

A five-health-state, state-transition model with time dependency was developed to estimate lifetime (38 years) costs and survival of resected EGFRm patients treated with adjuvant osimertinib or placebo (active surveillance), with/without prior adjuvant chemotherapy, using a

SUBMITTER: Verhoek A 

PROVIDER: S-EPMC10169948 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature